Literature DB >> 1825477

Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA).

P Y Fung1, B M Longenecker.   

Abstract

Epiglycanin (Epi) is a mucin-like glycoprotein carrying multiple Thomsen Freidenreich (TF) and Tn determinants secreted by a murine mammary adenocarcinoma, TA3-Ha. As an attempt to further characterize immunoregulatory networks in the TA3-Ha animal model, we tested whether Epi causes active suppression of the cell-mediated immune response against TF determinants. In this study, we show that (a) s.c. injection of epiglycanin emulsified in either complete Freund's adjuvant or Ribi adjuvant containing trehalose dimycolate and monophosphoryl lipid A elicits a classical specific delayed-type hyperactivity response to TF haptens either naturally expressed on epiglycanin or as synthetic haptens conjugated to a protein carrier; (b) i.v. injection of as little as 500 ng of Epi induces specific immunosuppression to anti-Epi and anti-TF synthetic antigen delayed-type hyperactivity responses; (c) this immunosuppression can be abrogated by i.v. injection of cyclophosphamide prior to immunizations; (d) Epi-induced specific immunosuppression can be adoptively transferred by nylon wool-nonadherent cells 6 days following i.v. injection of Epi; (e) pretreatment of suppressor cell populations with anti-Thy-1, anti-L3T4, anti-Lyt-1, or anti-I-Jk but not anti-Lyt-2 monoclonal antibodies plus complement prior to adoptive transfer abolished immunosuppression; (f) i.v. injection of immunosuppressive amounts of Epi on Days 2 and 6 after transplantation of TA3-Ha cells increased the lethality of the tumor transplant. These results suggest that Epi-induced specific immunosuppression in the TA3-Ha animal model is mediated by Thy-1+, L3T4+, Lyt-1+2-, and I-Jk+ suppressor cells. The results are also consistent with the suggestion that this immunosuppression may enhance TA3-Ha tumor growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825477

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Mucins and blastocyst attachment.

Authors:  Amantha Thathiah; Daniel D Carson
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

2.  Mucin 21/epiglycanin modulates cell adhesion.

Authors:  Yuri Yi; Mika Kamata-Sakurai; Kaori Denda-Nagai; Tomoko Itoh; Kyoko Okada; Katrin Ishii-Schrade; Akihiro Iguchi; Daisuke Sugiura; Tatsuro Irimura
Journal:  J Biol Chem       Date:  2010-04-13       Impact factor: 5.157

3.  PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors.

Authors:  Marcela A Haro; Chad A Littrell; Zhaojun Yin; Xuefei Huang; Karen M Haas
Journal:  Cancer Immunol Res       Date:  2016-11-08       Impact factor: 11.151

4.  Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis.

Authors:  Rob J Longman; Richard Poulsom; Anthony P Corfield; Bryan F Warren; Nicholas A Wright; Michael G Thomas
Journal:  J Histochem Cytochem       Date:  2006-08-21       Impact factor: 2.479

Review 5.  O-linked glycosylation in the mammary gland: changes that occur during malignancy.

Authors:  J M Burchell; A Mungul; J Taylor-Papadimitriou
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

6.  Autologous human B-cell immune response to pulmonary adenocarcinomatous polymorphic epithelial mucin.

Authors:  J Xiang; T Moyana; A Maksymiuk
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

7.  Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.

Authors:  G D MacLean; M Reddish; R R Koganty; T Wong; S Gandhi; M Smolenski; J Samuel; J M Nabholtz; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.

Authors:  Y F Zhai; W J Esselman; C S Oakley; C C Chang; C W Welsch
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine.

Authors:  Zhaojun Yin; Sudipa Chowdhury; Craig McKay; Claire Baniel; W Shea Wright; Philip Bentley; Katarzyna Kaczanowska; Jeffrey C Gildersleeve; M G Finn; Lbachir BenMohamed; Xuefei Huang
Journal:  ACS Chem Biol       Date:  2015-08-11       Impact factor: 5.100

10.  Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.

Authors:  L Ding; E N Lalani; M Reddish; R Koganty; T Wong; J Samuel; M B Yacyshyn; A Meikle; P Y Fung; J Taylor-Papadimitriou
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.